[dumbof]

Perk Labs Inc. Announces Appointment of Keith Roseland-Barnes to the Board of Directors and Issuance of U.S. Patent
VANCOUVER, BC / ACCESSWIRE / December 13, 2023 / Perk Labs Inc. (CSE:PERK)(OTC PINK:PKLBF)(FKT:PKLB) ("Perk" or the "Company"), today announced the appointment of Keith Roseland-Barnes to the Perk Board of Directors.

"We are pleased to welcome Keith Roseland-Barnes to the Perk Board", said Ryan Hardy, CEO of Perk Labs. "Keith brings a wealth of experience in technology leadership and software sales, with an outstanding record of consistently exceeding revenue targets in his more than 20 years of experience in technology sales and leadership."

Mr. Roseland-Barnes is the Chief Revenue Officer of Unravel Data, a market-leading data analytics and AI observability platform company, which helps teams turn complex data into actionable insights. "I am excited to be joining Perk's Board. Perk offers a very innovative and compelling mobile ordering and payment solution which allows venues and retailers to significantly enhance their customers' experience." said Mr. Roseland-Barnes. "I look forward to leveraging my experience to contribute to Perk's continued success and growth".

Issuance of U.S. Patent
The Company is also pleased to announce the issuance of its United States patent that protects the Company's rights to one of its inventions for systems and methods for electronic payments with fraud prevention, based on correlating transaction data and information from a user's device.

"We are pleased to enhance our intellectual property protection with this new patent issuance," said Ryan Hardy, CEO, Perk Labs. "The grant of this patent symbolizes the underlying capabilities of Perk as an innovative technology disruptor."

About Perk Labs Inc.
Perk Labs Inc., (CSE:PERK)(OTC PINK:PKLBF)(FKT:PKLB), the owner of Getit Technologies Inc. and Perk Hero Software Inc. ("Perk Labs"), provides innovative mobile ordering and payment systems, allowing customers the ability to scan a QR code or NFC sticker to order and pay for their purchases directly from their phone. Perk Labs specializes in providing a single unified payment interface for complex purchase environments - environments that have multiple retailers processing an array of different transactions, including food and beverage purchases, merchandise sales, ticketing, registrations, donations and even parking. Perk Labs provides a custom-branded solution that is ideal for multi-retailer venues such as stadiums and arenas, university and college campuses, conference centers, festivals, charity events and hotels and resorts.

For more information, contact:
Ryan Hardy
CEO
[phone]

[dumbof]

CSE: EPW | OTC: EPWCF |
EMPOWER CLINICS SIGNS MULTI-YEAR CLINICAL TRIAL CONTRACT WITH TOP 10 GLOBAL PHARMACEUTICAL COMPANY AND GENERATES FIRST REVENUES AS PATIENT RECRUITMENT COMMENCES

Multi-Year Contract With Top 10 Global Pharma Company Officially Launches Empower Clinics Pivot Into Global Pharmaceutical Clinical Trials. Multiple Active Trial Applications Anticipated Leading To Additional Big Pharma Due Diligence, Site Visits And Awards.


VANCOUVER, B.C. – November 30, 2023 – Empower Clinics Inc. (CSE: EPW OTC PINK: EPWCF) ("Empower" or the "Company") a prominent integrated healthcare company with a burgeoning focus on research and clinical trials for major pharmaceutical firms, is proud to announce a pivotal advancement. EPW Curesearch LLC (“EPWC”), a division of Empower, has executed a multi-year agreement with a top 10 global pharmaceutical company (“T10GPC”). This collaboration will concentrate on conducting critical clinical trials in the field of Chronic Obstructive Pulmonary Disease (“COPD Trials”) and has already resulted in generating initial revenues for the following key contract terms:
Up Front Administration Fees
Start Up Costs
Processing And General Administrative Fees,
Site Set Up Costs
Operational Training Fees For Site Staff
Pre-Screening & Recruitment Fees
Pharmacy Set Up Fee
These fees signify the commencement of the clinical and commercial relationship between Empower and the T10GPC.

LANDMARK CONTRACT MARKS EMPOWER CLINICS ENTRY INTO GLOBAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT
Steven McAuley, Chairman & CEO of Empower Clinics Inc. stated "This contract with one of the world’s leading pharmaceutical companies is a major milestone that marks Empower’s successful pivot from regional clinics to clinical trials on a global scale on behalf of all our shareholders. Suffice it to say this was a task of epic proportions that would not have been possible without our incredible team at EPW Curesearch - but now that we have arrived and have become a known entity in this massive global clinical trials market, we anticipate further such successes in the near future on our way to building a trusted and significant site management organisation.”

This landmark contract positions Empower Clinics at the forefront of respiratory health research, marking a pivotal moment in the company's expansion into pharmaceutical research and development. The agreement entails comprehensive clinical trials aimed at investigating new treatments for COPD, a progressive lung disease affecting millions worldwide and significantly impacting their quality of life.

CLINICAL TRIAL PATIENT ENROLLMENT METRICS AND ECONOMICS
The contract involves Phase III human trials, which will be meticulously conducted under the guidance of leading medical experts and researchers. Empower Clinics' state-of-the-art facilities and experienced team are well-equipped to undertake this significant research, ensuring the highest standards of scientific inquiry and patient safety.

This COPD trial is being led by one of our senior and most experienced principal investigators (PI)’s. Together, the Company, our PI and the T10GPC have established preliminary patient recruitment targets of 20-35 patients sourced mainly from the current roster of patients. The recruitment window is anticipated to remain open through mid 2024 with possible extensions allowed, and each patient’s involvement lasting fifty-two (52) weeks plus an additional twenty (20) weeks of follow up.

The T10GPC has put no limits on the maximum allowable patients for our site for the trial, which enables EPWC to recruit additional patients from outside sources such as other medical centers, hospitals and social recruitment channels including Facebook, Instagram, Twitter and other marketing methods.

Total fees under this COPD Trial agreement are expected to be on the upper end of initial expectations. Overall, the contract terms will allow the Company to bring important new revenue and cash flow.

Empower Clinics' advances into COPD research through this contract is expected to have a substantial impact on the company's growth and presence in the global healthcare market. It also reinforces the company's position as a leader in healthcare innovation and clinical research, further cementing its reputation as a company dedicated to improving patient care and outcomes.

EMPOWER CLINICS COMMITMENT TO CRITICAL HEALTHCARE AND IMPROVING PATIENT OUTCOMES
The collaboration with a top-tier global pharmaceutical entity underscores Empower Clinics' commitment to advancing medical research and providing cutting-edge healthcare solutions. The COPD study is expected to provide valuable insights into the treatment and management of the disease, potentially leading to breakthroughs in patient care.

Empower Clinics Inc., through its division EPW Curesearch LLC, has been consistently making strides in healthcare innovation. This new venture into COPD research highlights the company's dedication to addressing critical healthcare challenges and improving patient outcomes. COPD, characterized by increasing breathlessness, is a leading cause of morbidity and mortality worldwide, and the need for effective treatments has never been more urgent.

Steven McAuley added "Partnering with one of the world’s leading pharmaceutical companies for COPD research is not just an achievement for Empower Clinics but a beacon of hope for the millions of COPD patients globally whose lives could be dramatically improved through our research. We are fully committed to this cause, and our team is motivated by the potential to make a real difference in the world of respiratory healthcare”

As the clinical trials progress, Empower Clinics Inc. remains devoted to maintaining transparency and providing regular updates to stakeholders and the public. The company is confident that the outcomes of this research will contribute significantly to the body of knowledge in COPD treatment and set new benchmarks in respiratory healthcare.

Empower Clinics Inc. extends its gratitude to its partners, stakeholders, and dedicated team for their unwavering support and contributions towards making this project a reality. The company looks forward to a future where the findings from these clinical trials can be translated into effective treatments for COPD, improving the lives of patients around the globe.

For more information about Empower Clinics Inc., its divisions, and ongoing projects, please visit www.empowerclinics.com.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for
shareholder discussion, questions and engagement with management
https://agoracom.com/ir/EmpowerClinics
Sign up for your
Empower Clinics Investor Experience Pass
Thank you for being one of Empower Clinic's valued followers. The Empower Clinics Investor Experience pass is your gateway to exclusive content.
Click on the download button below!
SIGN UP
ABOUT EMPOWER:

Empower is a patient-focused healthcare company operating with the goal of positively impacting lives and future healthcare outcomes through clinical trials. The Company has launched two clinical research sites becoming a Site Management Organization (SMO) with six principal investigators (PI) with multiple clinical trials under application. Empower has announced its intention to create a proposed spinout with a focus on healthcare AI to support identification, recruitment, and onboarding of clinical trial patients.


ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer

CONTACTS:
Media:
Steven McAuley CEO [e-mail]
[phone]

Investors:
Tamara Mason
Business Development & Communications [e-mail]
[phone]

[dumbof]

https://mailchi.mp/c3efa85e7e97/empower-clinics-announces-proposal-for-division-spin-out-17449601?e=622a09b28b

[dumbof]

https://mailchi.mp/5e3aad76ecc0/empower-clinics-announces-proposal-for-division-spin-out-17448545?e=622a09b28b

[dumbof]

VANCOUVER, B.C., CANADA, September 25, 2023 /EINPresswire.com/ -- EMPOWER CLINICS INC (CSE:EPW) (PINK:EPWCF) ("Empower" or the "Company") a healthcare company with a developing research and clinical trials division announces its subsidiary EPW Curesearch LLC (“EPWC”) has been awarded its first clinical trial from a major European pharmaceutical company with a market cap over $100 Billion, who are conducting numerous global clinical trials that are impacting future healthcare outcomes.

The Company previously announced on July 31, 2023 that it had numerous study applications underway covering a variety of disease states. The Company can confirm the awarded clinical trial is focused on Chronic Obstructive Pulmonary Disease (COPD), and is being led by one of our senior and most experienced principal investigators (PI)’s.

Together, the Company, our PI and the sponsor have established preliminary patient recruitment targets of 20-35 patients sourced mainly from the current roster of patients. The recruitment window is anticipated to remain open through mid 2024 with possible extensions allowed, and each patient’s involvement lasting fifty-two (52) weeks plus an additional twenty (20) weeks of follow up. The sponsor has put no limits on the maximum allowable patients per site for the trial that enables EPWC to recruit additional patients from outside sources such as other medical centers, hospitals and social recruitment channels including Facebook, Instagram, Twitter and other marketing methods.

“We are all ecstatic to receive our first awarded clinical trial, that is a result of consistent and persistent effort over the past number of months. Our focus on partnering with large established medical centers and very experienced medical doctors has proven successful.” stated Steven McAuley, Chairman & CEO. “We continue to process multiple trial applications on behalf of our six (6) current PI’s, and as such anticipate additional sponsor due diligence, site visits and awards.”

PARTNERSHIP WITH SPECIALIST MEDICAL GROUPS

PI’s are practicing medical doctors who are specialists or internists with previous research and clinical trials experience. As such, they are integral to the success of any Site Management Organization (SMO) as follows:

? SMO leverages the medical practice of the PI’s and their patient rosters to generate new participants in active clinical trials and research, which in turn commences meaningful revenues from the Biotech and Pharmaceutical industries.
? SMO will provide oversight, direction and support to the PI’s and their patients.
? SMO will also act as a liaison between the pharmaceutical company and the assigned Contract Research Organization (CRO).
? Target trials typically span one to two years in length and can be extended if the trial has not yet gathered enough data or has not been closed.

CEASE TRADE ORDER AND ACCOUNTING AND AUDIT STATUS

The Company previously announced a Cease Trade Order effective August 15th, 2023 which remains in effect. Various audit and accounting procedures continue, and numerous technical decisions are being contemplated that may provide areas of audit simplification based on outcomes and Board recommendations. The Company is not in a position at this time to provide a firm commitment on expected completion of filings and resumption of trading. The Company anticipates it will provide regular updates in the future.

THE MARKET OPPORTUNITY IS SIGNIFICANT

The CRO Services Market in terms of revenue was estimated to be worth $76.6 billion in 2023 and is poised to reach $127.3 billion by 2028, growing at a CAGR of 10.7% from 2023 to 2028 according to a new report by MarketsandMarkets. Factors such as continuously growing pharmaceutical, biotechnology and medical device R&D pipelines and technological advancements in the clinical trials process are driving the growth of this market. In recent years, the costs associated with drug and product development have increased significantly, driving pharma, biotech and medical device companies to look for partnerships to drive modernizations and smarter ways of conducting business.

This press release is available on the Empower Clinics Verified Forum on

[Renee]

EPWCF: SEC Admin. Proceeding for severely delinquent Financials: (last 20-F filed on Dec. 18,2018)

https://www.sec.gov/files/litigation/admin/2023/34-98315.pdf

[Renee]

EPWCF one for 5 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[dumbof]

https://pro.ceo.ca/@accesswire/empower-clinics-reports-q4-2022-results

by @accesswire on 28 Feb 2023, 23:00
Empower Clinics Reports Q4 2022 Results

46% year over year increase in gross profit margin and 7% Increase in Revenue

VANCOUVER, BC / ACCESSWIRE / February 28, 2023 / EMPOWER CLINICS INC (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") a life sciences healthcare company - serving patients through medical centers, a medical device company and the application of clinical studies that leverages it's high complexity medical diagnostics laboratory - announced today it has filed its Q4 2022 interim consolidated financial statements and related management's discussion & analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated. On December 23, 2022, the Company announced it has changed its fiscal year end from December 31 to March 31.

"I am proud of our team and their efforts to maintain growth initiatives, all while managing costs going into 2023." said Steven McAuley, Chairman & CEO. "Going forward, we continue to develop our U.S. healthcare initiatives focusing on offering clinical trial services, with the stated objective of becoming an established Site Management Organization (SMO) for the pharmaceutical, biotechnology and medical device industries."

Q4 2022 Highlights

Total revenues from continuing operations of $426,786 for Q4 2022 compared to revenues of $1,142,581 for Q4 2021, representing a 63% decrease year over year. The decrease in revenue was mainly attributed to the decrease in COVID-19 testing services.
Gross margin from continuing operations was 16% for Q4 2022, compared to a negative gross margin of 25% in Q4 2021. The increase in gross margin resulted from savings in personnel costs.
Net loss from continuing operations was $2,370,651 or $0.01 per share compared to a net loss from continuing operations of $4,684,114 or $0.01 per share for Q4 2021.
Cash as at December 31, 2022 was $193,144, compared to cash of $866,170 at December 31, 2021.
Cash used in operating activities from continuing operations was $447,013 for Q4 2022, compared to $778,897 for Q4 2021.
Financial Summary

$, except where noted
Three months ended
December 31,
Twelve months ended
December 31,
2022 2021 2022 2021
Total revenues
426,786 1,142,581 4,661,525 4,368,916
Direct clinic expenses
(359,668 ) (1,428,074 ) (2,693,502 ) (3,020,412 )
Loss from operations
(1,194,869 ) (2,361,586 ) (4,954,313 ) (5,441,952 )
Net loss from continuing operations
(2,370,651 ) (4,684,114 ) (2,960,787 ) (31,736,245 )
Adjusted EBITDA loss
(2,737,185 ) (2,250,620 ) (5,761,969 ) (3,848,456 )
Net loss per share, continuing operations, basic and diluted
(0.01 ) (0.01 ) (0.01 ) (0.10 )
Financial Performance

As part of total revenues, revenues from the Health & Wellness segment for Q4 2022 were $151,659 compared to Q4 2021 revenues of $256,254. This decrease over the prior year period is attributable to lower revenues from Medi-Collective's clinics.

Diagnostics & Technology revenue includes the sale of MediSure products and laboratory testing services conducted by MediSure Laboratory and Empower Clinics. Diagnostics & Technology revenue for Q4 2022 were $275,127 compared to $886,327 in Q4 2021. The decrease in revenue was due to reduced Covid-19 testing in the United States as well as other laboratory services in the current year period. Of the total revenue in Q4 2022, 98% was attributable to the sale of medical equipment in MediSure.

Direct expenses excluding depreciation and amortization for Q4 2022 were $359,668 compared to Q4 2021 direct clinic expenses of $1,428,074. The decrease in direct expenses was due to the decrease in operating activities, primarily personnel costs, associated with providing Covid-19 testing services.

Loss from operations for Q4 2022 was $1,194,869 compared to Q4 2021 of $2,361,586. This decrease in loss over the prior year comparable quarter is primarily due to reduced advertising and promotion activities and legal and professional fees.

Net loss from continuing operations for Q4 2022 was $2,370,651 compared to Q4 2021 of $4,684,114. In Q4 2021, the Company recognized aggregate impairment charges of $5,222,249, while no impairment was recorded in Q4 2022. This difference was offset by a loss on debt settlement of $1,873,901 in the current year period and a lower gain on change in fair value of warrant liability and conversion features associated with convertible debentures in Q4 2022.

Adjusted EBITDA is a non-GAAP financial measure that is calculated as net loss from continuing operations before depreciation and amortization, interest, accretion, share-based compensation, changes in the fair value of derivative liabilities and extraordinary items such as impairment. Adjusted EBITDA loss in Q4 2022 was $863,284compared to $2,250,620 in Q4 2021. Adjusted EBITDA is a metric used by management to monitor the Company's revenues compared to its cash operating costs in an effort to trend toward improved profitability.

During Q4 2022, the Company used $447,013 of cash in operating activities of continuing operations. The Company invested cash of $754 for the purchase of furniture and equipment and had $186,396 of cash provided by financing activities from the issuance of units and convertible debentures offset by lease payments and consideration payable.

Please refer to Empower's condensed interim consolidated financial statements, related notes and accompanying management's discussion & analysis for a full review of the Company's operations.

About Empower

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer

CONTACTS:

Investors

Tamara Mason

Steven McAuley

Business Development & Communications

CEO

1-855-855-9058

1-855-855-9058

[e-mail]

[e-mail]

[dumbof]

https://finance.yahoo.com/news/empower-clinics-subsidiary-signs-laboratory-083000846.html

[dumbof]

https://ceo.ca/@accesswire/empower-clinics-reports-record-annual-revenue-and-fiscal

[dumbof]

https://ceo.ca/@accesswire/empower-clinics-sees-continued-strong-volume-for-its

[dumbof]

https://pro.ceo.ca/@accesswire/empower-clinics-unveils-medisure-brand-in-the-united

by @accesswire on 20 Jun 2022, 10:45
Empower Clinics Unveils Medisure Brand In the United States

Empower rebrands medical divison in the U.S. and accelerates access to the largest hospitals, medical centers and cruiseship opportunites

VANCOUVER, BC / ACCESSWIRE / June 20, 2022 / EMPOWER CLINICS INC (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company offering services in the U.S. and Canada - announced a corporate rebrand of its medical diagnostics laboratory business in the U.S. to Medisure Laboratory, and opens opportunities to the largest healthcare centers in the state of Texas, and leverages its cruiseship connections to the largest ports in the U.S.

The new brand marks an important milestone in the evolution of Empower's presence in the U.S. healthcare market. It represents a fresh and forward-looking approach to the healthcare community, leveraging the Medisure brand as a leading medical device and testing company, to access and support the largest hospital networks with laboratory services in the state of Texas, the cruiseship industry, and film & television productions.

With the company's experience and reputation, and deep connections to major cruiseline's, Empower and its accredited laboratory in Texas, have expanded its service offering to key ports in the southern U.S. As a COLA and CLIA accredited laboratory, the company can provide testing and healthcare services to key industries such as film & television, that require testing and healthcare management solutions.

"The Medisure brand is strong, and embodies the energy and growth that we have for our business in the U.S. market." stated Steven McAuley, Chairmain and CEO, "Launching Medisure Labs in the U.S. and utilizing our investments just makes sense, it opens new doors, allows us to bring products to market and grow more rapidly. With Medisure Labs, we have a proven brand serving many thousands of patients, that is primed to succeed in the world's largest healthcare market."

Immediate plans for Medisure include researching, applying for and securing additional U.S. Federal Drug and Administration (FDA) certifications to allow for the sale of its medical devices in the U.S. Medisure is also upgrading its quality managements systems to expedite the certification process. The company has advanced its offers to the cruiseship industry and to film & television productions.

The new website for Medisure Laboratory is www.medisurelabs.com

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Media:

Steven McAuley CEO
[e-mail]
604-227-0865

Investors:

Tamara Mason

Business Development & Communications
[e-mail]
604-359-9107

[dumbof]

https://ceo.ca/@accesswire/empower-clinics-exceeds-3000-tests-and-750-appointments

by @accesswire on 1 Jun 2022, 09:10
Empower Clinics Exceeds 3000 Tests and 750 Appointments for its Testing Solutions in Vancouver in First Month of Operations

Expectations exceeded in first full month of operations while still early in cruise travel season

VANCOUVER, BC / ACCESSWIRE / June 1, 2022 / EMPOWER CLINICS INC (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers and testing clinics, telemedicine platforms, a medical device company, and a high complexity medical diagnostics laboratory - announced today its COVID-19 testing solutions offered in and around Vancouver's Port of Vancouver and Canada Place has exceeded 3000 tests and confimed more than 750 pending appointments going forward in just its first full month of operation.

All of Empower's COVID-19 testing solutions are fully accredited by the College of Physicians and Surgeons of British Columbia's Diagnostic Accreditation Program (DAP). All COVID-19 testing in British Columbia requires accreditation by the College's Diagnostic Accreditation Program (DAP). Empower's fully accredited COVID-19 testing solutions includes three certified sites at the Port of Vancouver, Canada Place and Fairmont Waterfront Hotel as well as a recently accredited concierge mobile service.

"Serving well over 3000 clients is an important milestone for our accredited testing solutions in Vancouver providing significant new cash flow for the company and supporting our investment thesis for this project," stated Steven McAuley, Chairman and CEO of Empower Clinics. "It reasserts the importance and investment that we've made to be a fully accredited operation as per local B.C. regulation. It also allows our entire team, clients and shareholders to find confidence in the stability, quality and potential reach of our services while we are still early in the cruise season and peak tourist season for Vancouver - with countless conferences, tour groups and events -just ahead of us."

For more than 35 years, Vancouver has been a leading homeport for cruises to Alaska and is the only homeport to offer both one-way and roundtrip itineraries through Canada's scenic Inside Passage to Alaska. Prior to the pandemic, forecasts indicated record growth in demand for cruises to Alaska, and demand is expected to remain strong in the future. The Vancouver cruise industry is a key contributor to the local economy, helping generate $3.17 million (CAD) in direct economic activity for each ship that calls at Canada Place and $2.2 billion (CAD) of total economic impact.

Royal Carribean - the world's second largest cruise operator - refers its clients to Empower Clinics COVID-19 testing solutions on the Frequenty Asked Questions section of their website. https://www.royalcaribbean.com/faq/questions/what-if-i-dont-find-a-pre-cruise-test-or-get-test-results-in-time.

With severals ships carrying more than 4000 people, the Vancouver Fraser Port Authority expects more than 300 cruise ship calls for the 2022 season - nearly an 8% increase from 288 calls in pre-pandemic 2019.

Passengers can visit https://www.empowerclinics.com/covid-19-testing/ to book COVID-19 testing solutions that include virtual (telehealth) or in-person Rapid Antigen / Rapid PCR (RT-Lamp) testing at a site at Fairmont Waterfront Hotel - adjacent to the port terminal at Canada Place. Pricing of solutions range from $100 CAD to $250 CAD per test.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Media:
Steven McAuley CEO
[e-mail]
604-227-0865

Investors:
Tamara Mason
Business Development & Communications
[e-mail]
604-359-9107

[dumbof]

https://ceo.ca/cbdt

[Smokey1979]

What is up with this stock?

[dumbof]

by @accesswire on 27 Sep 2021, 14:30
Empower Clinics and SoLVBL Solutions Sign Memorandum of Understanding (MoU) to Develop a Program for Data Security in Diagnostic Testing

Enhanced Data Verification Will Augment Empower's Integrated Technology Services and Goals

VANCOUVER BC / ACCESSWIRE / September 27, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(FRA:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens - is pleased to announce it has signed a Memorandum of Understanding with SoLVBL Solutions Inc. ("SoLVBL Solutions") to develop a cyber security program to detect cyber-attacks and provide data security to the diagnostic testing programs used by Empower.

SoLVBL Solutions is at the forefront of developing cybersecurity solutions and advanced unique capabilities for providing customers with capabilities to protect and verify incoming data against a range of cyber threats. The novel solution powered by SOLV's underlying technology, will incorporate dedicated data security mechanisms for Empower's diagnostic testing platform. As healthcare service providers face increased cybersecurity threats, the need for effective and resilient data security is paramount to maintain seamless healthcare services.

"We are excited to collaborate with SoLVBL Solutions, a company with broad know-how in data verification and cybersecurity. The collaboration agreement entered with Empower combines SoLVBL Solutions' data verification capabilities with Empower's experience and extensive expertise in the design, construction, operation, and maintenance of healthcare clinics and world-class diagnostic laboratories. With the increase in data collection, the demand to protect and verify data is unprecedented. We have seen such announcements come from both the Canadian and American governments. We feel this verification solution will allow us to continue to grow and meet the demands and needs of our patients and health care administrations. The collaboration aligns with our expansion and growth plans to become a global technological leader in the healthcare diagnostic sector." said Steven McAuley, CEO of Empower.

"We are extremely proud that SoLVBL Solutions' collaboration with Empower will yield a comprehensive cybersecurity solution for Empower's diagnostic testing platforms, answering a growing global cyber threat. We believe this will be the first of many such opportunities in the healthcare vertical, and one that we realized was needed and doable in our ongoing conversations with the Empower team. Together we realized the need for this level of data protection in this sector." said Raymond Pomroy, CEO of SoLVBL Solutions.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT SOLVBL SOLUTIONS INC.
SoLVBL Inc.™ takes a different approach to cybersecurity with its proprietary Q by SoLVBL™ protocol that quickly and cost-effectively establishes the authenticity of digital records at very high speed. We don't believe that any system is ‘un-hackable', no matter how secure it appears to be, and if a system can be hacked, the data within that system is subject to manipulation. Bad data leads to bad decisions. Our Mission: ‘To empower better, faster decisions by developing a universal standard for establishing digital record authenticity which is easy to adopt, cheap to use, offers cryptographic assurances, and will not bottleneck systems.'. The Company is currently pursuing the following verticals: chain of custody for digital evidence including NG-911; data used in the financial sector; medical applications; and critical IoT infrastructures.

ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer

CONTACTS:
Investors:
Steven McAuley CEO
[e-mail] 604-789-2146

Investors:
Tamara Mason
Business Development & Communications
[e-mail]
416-671-5617

[dumbof]

by @accesswire on 23 Sep 2021, 14:31
Empower Clinics Launches Its Next "The Medi-Collective" Clinic; Expands Pipeline of Clinics To 33 locations including Alberta, British Columbia, and New Brunswick

Empower Officially Enters National Clinic Rollout Phase Under The Medi Collective Brand

VANCOUVER, BC / ACCESSWIRE / September 23, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (EPWCF:OTCQB) (8EC:Frankfurt) ("Empower" or the "Company") an integrated healthcare company serving patients through medical centers, telemedicine platforms, a medical device company, and a high complexity medical diagnostics laboratory processing COVID-19 specimens and developing a variety of direct to consumer testing protocols, is pleased to announce the expansion of its national clinic rollout strategy with the expected grand opening of "The Medi-Collective" ("TMC") clinic in Etobicoke, Ontario on October 18th, 2021.

Furthermore, Empower is pleased to provide shareholders with an update on the progress of its Canadian nationwide clinic expansion strategy, which now includes a pipeline of 33 clinic locations at various stages of development, including our first clinic locations outside of Ontario.

SAVE THE DATE - SHAREHOLDERS INVITED TO OCTOBER 18TH GRAND OPENING CEREMONY IN ETOBICOKE, ONTARIO

On September 8th Empower announced the official opening of its inaugural TMC medical clinic in Hamilton, Ontario. On October 18th Empower shareholders are invited to the grand opening and ribbon cutting ceremony of our new TMC clinic at 440 Brown's Line, Etobicoke, ON M8W 3T9, which will include CEO Steven McAuley, Dr. Jordan Rabinowitz and Dr. Aviv Tsimerman, as well as VIP guests from the financial, medical, and political sectors.

Guests will have an opportunity to experience the 2,600 square foot clinic and meet the medical staff firsthand, to truly visualize the TMC model for expansion across Canada - all while enjoying great food, TMC swag, photo opportunities and conversations with Company management.

"I could not be more excited for our company and shareholders to see our investment in Brownsline and the City of Etobicoke come together and be fully open to serve patients." said Steven McAuley, Chairman & CEO Of Empower Clinics. "We are all living though challenging times, yet I have watched our outstanding team members be optimistic, persevere and never waiver from our goals. We are a collective, we care about our patients, the communities we serve, our shareholders, and we look forward to many more grand openings."

CLINIC PIPELINE UPDATED TO INCLUDE 33 LOCATIONS AND SPANNING 4 PROVINCES THANKS TO GREATER THAN EXPECTED DEMAND FROM DOCTORS AND PHARMACY PARTNERS. OPENINGS PROJECTED EVERY 3 WEEKS THROUGH THE END OF 2021 AND INTO Q1 2022

The Company is pleased to advise shareholders that our pipeline of clinics continues to expand rapidly, even more than anticipated, thanks to greater than expected interest from doctors and pharmacy partners who want to be involved with The Medi-Collective brand. This now extends beyond Ontario and into the provinces of:

Alberta
British Columbia
New Brunswick
The status of our clinic pipeline in Canada can be summarized as follows:

OPERATING - 3
IN DEVELOPMENT & CONSTRUCTION - 9
IN DUE DILIGENCE - 21
TOTAL - 33

Advanced discussions continue for additional locations nationwide, as the Company gains momentum on its Canadian roll out strategy.

"Our decision to align with pharmacy brands both national and independent across Canada is proving to be so beneficial. Together we support patients and people in the communities we serve. Together, we bring greater access to care, providing advanced specialist services under one roof, both in-clinic and through telemedicine and virtual care." Empowers Chairman & CEO Steven McAuley further states, "We are leveraging our R&D and product divisions to ensure people everywhere have more control over their personal healthcare outcomes. Wellness matters, it matters to me, it matters to our team members, it matters to our shareholders, it matters to our partners, it matters to the patients and communities we serve."

HEALTH CARE SERVICES TO BE DELIVERED AND ANTICIPATED REVENUES

Empower, though The Medi Collective division, is opening primary care and para-medical healthcare services in its clinics.

Primary care services include:

Family physicians
Walk-in physicians
Tele-medicine and virtual care
The Company anticipates it could generate $400,000 - $600,000 in annual revenue per MD, per location, which equates to a revenue range between $1,600,000 - $2,400,000 annually per location.

Paramedical services include:

Chiropractic
Physiotherapy
Registered Massage Therapy
Chiropody
Acupuncturists
Osteopaths
Nutritionists
The Company anticipates it could generate $960,000 - $1,200,000 in annual revenue per location with Paramedical services

When locations are fully operational, Empower anticipates it could generate $2,560,000 - 3,600,000 in annual revenue per location on a weighted average fully operational basis.

ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED

Given the anticipated rapid expansion and penetration of Empower and The Medi Collective brand into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:

Tele-Dermatology
On March 10th Empower and MedX Health Corporation (TSX-V: MDX) announced an MOU to pilot MedX's tele-dermatology screening platform at two select Empower Clinics locations in Ontario, with plans for a broader market roll-out pending the completion of a successful pilot.

Cardiology
Empower continues to have ongoing discussions with a variety of cardiology specialists and is reviewing cardiology product opportunities that the MediSure brand could bring to market.

The Company believes these additional services hold the potential to add significant value to the operations of each healthcare centre.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions, and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and a world-class medical diagnostics laboratory. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:

Steven McAuley CEO
[e-mail]
604-789-2146

Investors:

Tamara Mason
Business Development & Communications
[e-mail]
416-671-5617

[dumbof]

Empower Clinics Uplisted - Will Begin Trading on OTCQB Market
posted on Sep 10, 2021 10:50AM
Log in to use the IP Check tool [?]
OTCQB Market Provides Greater Access to Empower Shares in the U.S.

VANCOUVER BC / ACCESSWIRE / September 10, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens - announced today that its common shares will be added to the OTCQB Venture Market (the "OTCQB") at market open on September 10, 2021, under the symbol "EPWCF."

"This is an extremely exciting announcement for Empower's market presence in the U.S.," said Steven McAuley, Chairman and CEO of Empower Clinics. "Empower shares are now accessible to a trove of new U.S. based retail and institutional investors. This expanded visibility is a huge step forward as we continue our aggressive North American expansion in the integrated healthcare space."

The OTCQB is a well-regarded public financial market for international companies across a variety of sectors. It's an ideal next step for Empower Clinics as the market has a particular focus on entrepreneurial and fast-developing companies. The market's high financial and corporate standards speak to the progress of Empower Clinics. Following a rigorous approval process, successful companies receive access to a diversified base of U.S. retail and institutional investors in addition to the opportunity to increase the Company's visibility and liquidity.

Empower's shares will continue to be listed on the Canadian Securities Exchange (CSE) under the ticker symbol "CBDT," as well as on the Frankfurt Stock Exchange (FRA) under the ticker symbol "8EC." ?

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:

Steven McAuley CEO
[e-mail]
604-789-2146

Investors:

Tamara Mason
Business Development & Communications
[e-mail]
416-671-5617

[dumbof]